| Cardiovascular events and intensity of treatment in polycythemia vera R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ... New England Journal of Medicine 368 (1), 22-33, 2013 | 934 | 2013 |
| Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study R Cairoli, A Beghini, G Grillo, G Nadali, F Elice, CB Ripamonti, ... Blood 107 (9), 3463-3468, 2006 | 483 | 2006 |
| Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients W Barcellini, B Fattizzo, A Zaninoni, T Radice, I Nichele, E Di Bona, ... Blood, The Journal of the American Society of Hematology 124 (19), 2930-2936, 2014 | 371 | 2014 |
| Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study L Pagano, CG Valentini, A Pulsoni, S Fisogni, P Carluccio, F Mannelli, ... Haematologica 98 (2), 239, 2013 | 354* | 2013 |
| Dasatinib–blinatumomab for Ph-positive acute lymphoblastic leukemia in adults R Foà, R Bassan, A Vitale, L Elia, A Piciocchi, MC Puzzolo, M Canichella, ... New England Journal of Medicine 383 (17), 1613-1623, 2020 | 334 | 2020 |
| Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome D Rossi, M Cerri, D Capello, C Deambrogi, FM Rossi, A Zucchetto, ... British journal of haematology 142 (2), 202-215, 2008 | 300 | 2008 |
| Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia K Meldi, T Qin, F Buchi, N Droin, J Sotzen, JB Micol, D Selimoglu-Buet, ... The Journal of clinical investigation 125 (5), 1857-1872, 2015 | 193 | 2015 |
| Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome L Malcovati, MG Della Porta, M Lunghi, C Pascutto, L Vanelli, ... Leukemia 19 (5), 776-783, 2005 | 161 | 2005 |
| Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program L Maurillo, A Venditti, A Spagnoli, G Gaidano, D Ferrero, E Oliva, ... Cancer 118 (4), 1014-1022, 2012 | 153 | 2012 |
| Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program P Musto, L Maurillo, A Spagnoli, A Gozzini, F Rivellini, M Lunghi, O Villani, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 131 | 2010 |
| Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment‐related risk factors M Ruggeri, A Tosetto, F Palandri, N Polverelli, MG Mazzucconi, C Santoro, ... Journal of Thrombosis and Haemostasis 12 (8), 1266-1273, 2014 | 116 | 2014 |
| Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma D Rossi, E Berra, M Cerri, C Deambrogi, C Barbieri, S Franceschetti, ... haematologica 91 (10), 1405-1409, 2006 | 111 | 2006 |
| Leukemic transformation of polycythemia vera: a single center study of 23 patients F Passamonti, E Rumi, L Arcaini, C Castagnola, M Lunghi, P Bernasconi, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 101 | 2005 |
| Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA … S Amadori, R Stasi, AM Martelli, A Venditti, G Meloni, F Pane, G Martinelli, ... British journal of haematology 156 (2), 205-212, 2012 | 92 | 2012 |
| Zoledronic acid down‐regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect A Corso, E Ferretti, M Lunghi, P Zappasodi, S Mangiacavalli, M De Amici, ... Cancer 104 (1), 118-125, 2005 | 89 | 2005 |
| Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP M Baccarani, E Abruzzese, V Accurso, F Albano, M Annunziata, S Barulli, ... Blood advances 3 (24), 4280-4290, 2019 | 81 | 2019 |
| Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia‐negative chronic myeloproliferative disorders D Capello, C Deambrogi, D Rossi, T Lischetti, D Piranda, M Cerri, V Spina, ... British journal of haematology 141 (4), 504-511, 2008 | 81 | 2008 |
| First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia … G Martinelli, A Piciocchi, C Papayannidis, S Paolini, V Robustelli, ... Blood 130, 99, 2017 | 75 | 2017 |
| A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia V Santini, B Allione, G Zini, D Gioia, M Lunghi, A Poloni, D Cilloni, ... Leukemia 32 (2), 413-418, 2018 | 74 | 2018 |
| Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers W Barcellini, A Zaninoni, B Fattizzo, JA Giannotta, M Lunghi, A Ferrari, ... American Journal of Hematology 93 (9), E243-E246, 2018 | 61 | 2018 |
